Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.06%88 Pretax Margin % is 12.31% as of Mar. 2026, which is 22% below its 10-year median of 15.82. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Guobang Pharma ranks better than 69.37% on this metric.
The historical rank and industry rank for Guobang Pharma's Pretax Margin % or its related term are showing as below:
SHSE:605507'
s Pretax Margin % Range Over the Past 10 Years
Min: 13.04 Med: 15.82 Max: 22.43
Current: 14.6
SHSE:605507's Pretax Margin % is ranked better than 69.37% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.17
vs SHSE:605507: 14.60
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Guobang Pharma Pretax Margin % Related Terms
Guobang Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a Pretax Margin % of 12.31% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Guobang Pharma and its competitors. This is 22% below median its historical median of 15.82. Over the past decade, Guobang Pharma's Pretax Margin % has ranged from 13.04 to 22.43. According to the industry distribution chart, Guobang Pharma ranks #294 out of 960 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Guobang Pharma's Pretax Margin % too high?
Guobang Pharma's current Pretax Margin % of 12.31% is 22% below median its 10-year median of 15.82. Over the past 10 years, this metric has ranged from a low of 13.04 to a high of 22.43. The Drug Manufacturers industry median Pretax Margin % is 7.17. Guobang Pharma's value of 12.31% is 71.7% above this industry median. Based on the distribution chart, Guobang Pharma ranks #294 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #294 out of 960 companies for Pretax Margin %. This puts Guobang Pharma in the upper half of its industry. The industry median Pretax Margin % is 7.17. Guobang Pharma's value of 12.31% is 71.7% above this benchmark. Historically, Guobang Pharma's own Pretax Margin % has ranged from 13.04 to 22.43 over the past decade. While the company's 10-year median is 15.82 vs. the industry median of 7.17, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.17, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current Pretax Margin % of 12.31% is 71.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current Pretax Margin % is 12.31%, which is 22% below median its own 10-year median of 15.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.30 — trading 1.9% above its estimated fair value. The current Pretax Margin % is 12.31%, which is 22% below median its 10-year median of 15.82 and 71.7% above the Drug Manufacturers industry median of 7.17. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Pretax Margin % is 12.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.30 is trading 1.9% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
Pretax Margin %: 12.31% (22% below median its 10-year median of 15.82)
GF Value™: ¥16.00 vs. price of ¥16.30 (1.9% above fair value)
Industry Position: 71.7% above the Drug Manufacturers median (#294 of 960)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
